These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 2791441)
1. The future of automated record linkage for postmarketing surveillance: a response to Shapiro. Faich GA; Stadel BV Clin Pharmacol Ther; 1989 Oct; 46(4):387-9. PubMed ID: 2791441 [No Abstract] [Full Text] [Related]
2. Automated record linkage: a response to the commentary and letters to the editor. Shapiro S Clin Pharmacol Ther; 1989 Oct; 46(4):395-8. PubMed ID: 2791442 [No Abstract] [Full Text] [Related]
3. The role of automated record linkage in the postmarketing surveillance of drug safety: a critique. Shapiro S Clin Pharmacol Ther; 1989 Oct; 46(4):371-86. PubMed ID: 2535647 [No Abstract] [Full Text] [Related]
4. Record linkage for postmarketing surveillance. Faich GA Clin Pharmacol Ther; 1989 Oct; 46(4):479-80. PubMed ID: 2791451 [No Abstract] [Full Text] [Related]
5. Uninformed criticism of automated record linkage. Vick H; Walker AM Clin Pharmacol Ther; 1989 Oct; 46(4):478-9. PubMed ID: 2791450 [No Abstract] [Full Text] [Related]
6. Electronic Reporting for Clinical Drug Safety and Pharmacovigilance. 29 - 30 October 2002, Amsterdam, The Netherlands. Hennig R Expert Opin Drug Saf; 2003 Mar; 2(2):195-7. PubMed ID: 12904118 [TBL] [Abstract][Full Text] [Related]
7. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Stergachis AS Drug Intell Clin Pharm; 1988 Feb; 22(2):157-61. PubMed ID: 3349931 [TBL] [Abstract][Full Text] [Related]
8. Automated data bases used for pharmacoepidemiology research. Strom BL; Carson JL Clin Pharmacol Ther; 1989 Oct; 46(4):390-4. PubMed ID: 2535648 [No Abstract] [Full Text] [Related]
11. The role of record linkage in post-marketing drug surveillance. Crombie IK Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):77S-82S. PubMed ID: 3567036 [No Abstract] [Full Text] [Related]
13. Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions. Venning GR Br Med J (Clin Res Ed); 1983 Feb; 286(6364):544-7. PubMed ID: 6402143 [TBL] [Abstract][Full Text] [Related]
14. The future of pharmacovigilance: a personal view. Edwards IR Eur J Clin Pharmacol; 2008 Feb; 64(2):173-81. PubMed ID: 18172624 [No Abstract] [Full Text] [Related]
15. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges. Issa AM Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471 [TBL] [Abstract][Full Text] [Related]
16. Expanding roles of hospital epidemiology: pharmacoepidemiology. Burke JP; Tilson HH; Platt R Infect Control Hosp Epidemiol; 1989 Jun; 10(6):253-4. PubMed ID: 2661681 [No Abstract] [Full Text] [Related]
17. Postmarketing drug surveillance by record linkage in Tayside. Crombie IK; Brown SV; Hamley JG J Epidemiol Community Health; 1984 Sep; 38(3):226-31. PubMed ID: 6470600 [TBL] [Abstract][Full Text] [Related]
18. Drug-safety pilot makes the grade. Ledford H Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456 [No Abstract] [Full Text] [Related]
19. Post-marketing surveillance in the UK (1984). Lawson DH Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035 [No Abstract] [Full Text] [Related]